Overexpression of < em > MYBL2 < /em > predicts poor prognosis and promotes oncogenesis in endometrial carcinoma

Endometrial cancer (EC) is the most common gynecologic malignancy and still remains clinically challenging. We aimed to explore the potential biomarkers of EC and provide a theoretical basis for early screening and targeted therapy. The available transcriptome data from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) were analyzed to identify differentially expressed genes. Immunohistochemistry was performed to detect gene expression. We analyzed the associations ofMYBL2 with clinicopathological features and survival time and the biological effect ofMYBL2 on the proliferation of EC cells. The effect ofMYBL2 silencing on the transcriptome of EC cell model was analyzed by RNA-Seq.MYBL2 was significantly upregulated with obvious copy number alteration (CNA) in EC. Copy number amplification significantly increasedMYBL2 mRNA expression, which led to a poor prognosis and severe pathological types of EC. Additionally,MYBL2 silencing significantly inhibited proliferation and induced apoptosis and G1-phase cell cycle arrest in EC cell lines. Our results indicate thatMYBL2 is closely related to the cell cycle and apoptosis pathways in EC. The findings in this study provide evidence thatMYBL2 can serve as a new candidate prognostic marker and a target for future therapeutic intervention in EC.
Source: European Journal of Histochemistry - Category: Biomedical Science Authors: Source Type: research